Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | |||
| Net Income | -42,280 | N/A | N/A |
| Depreciation Amortization | 1 | N/A | N/A |
| Accounts payable and accrued liabilities | 1,418 | N/A | N/A |
| Other Working Capital | 2,599 | N/A | N/A |
| Other Operating Activity | 1,565 | 0 | 0 |
| Operating Cash Flow | $-36,697 | $N/A | $N/A |
| Cash Flows From Investing Activities | |||
| PPE Investments | -151 | N/A | N/A |
| Investing Cash Flow | $-151 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||
| Debt Issued | 16,554 | N/A | N/A |
| Debt Repayment | 263 | N/A | N/A |
| Common Stock Issued | 48 | N/A | N/A |
| Other Financing Activity | 29,958 | 0 | 0 |
| Financing Cash Flow | $46,823 | $N/A | $N/A |
| Beginning Cash Position | 3,091 | N/A | N/A |
| End Cash Position | 13,066 | N/A | N/A |
| Net Cash Flow | $9,975 | $N/A | $N/A |
| Free Cash Flow | |||
| Operating Cash Flow | -36,697 | N/A | N/A |
| Capital Expenditure | -151 | N/A | N/A |
| Free Cash Flow | -36,848 | 0 | 0 |